Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
+0.14 (0.50%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.68 - 28.32
52 week 16.72 - 32.50
Open 27.96
Vol / Avg. 4.68M/2.73M
Mkt cap 8.28B
P/E 56.83
Div/yield     -
EPS 0.49
Shares 295.85M
Beta 1.88
Inst. own 83%
Feb 26, 2018
Q4 2017 Exelixis Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 19, 2018
Exelixis Inc and Ipsen SA Financial Community Briefing for Data Presented at ASCO-GI - Webcast
Nov 29, 2017
Exelixis Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - Webcast
Nov 28, 2017
Exelixis Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 14, 2017
Exelixis Inc at Stifel Healthcare Conference - Webcast
Nov 7, 2017
Exelixis Inc at Credit Suisse Healthcare Conference - Webcast
Nov 1, 2017
Q3 2017 Exelixis Inc Earnings Call - Webcast
Nov 1, 2017
Q3 2017 Exelixis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 53.36% -36.68%
Operating margin 53.23% -21.95%
EBITD margin - -13.69%
Return on average assets 57.96% -15.13%
Return on average equity 168.60% -
Employees 287 -
CDP Score - -


210 E Grand Ave
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board, Co-Founder
Age: 68
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Christopher J. Senner Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. President - Product Development and Medical Affairs, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Scientific Strategy, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Jeffrey J. Hessekiel J.D. Executive Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Patrick Haley Senior Vice President - Commercial
Age: 41
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq. Independent Director
Age: 73
Bio & Compensation  - Reuters
Alan M. Garber M.D. Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters